BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2021 8:09:41 AM | Browse: 433 | Download: 596
 |
Received |
|
2021-05-08 12:46 |
|
Peer-Review Started |
|
2021-05-08 12:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-13 21:54 |
|
Revised |
|
2021-05-18 14:19 |
|
Second Decision |
|
2021-08-18 03:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-08-18 09:25 |
|
Articles in Press |
|
2021-08-18 09:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-09-17 03:00 |
|
Publish the Manuscript Online |
|
2021-09-22 08:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Drug-induced liver injury and COVID-19: A review for clinical practice
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gabriela Xavier Ortiz, Gabriele Lenhart, Matheus William Becker, Karin Hepp Schwambach, Cristiane Valle Tovo and Carine Raquel Blatt |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Matheus William Becker, MSc, Pharmacist, Research Scientist, Graduate Program in Medicine Hepatology, Federal University of Health Sciences of Porto Alegre, Sarmento Leite, 245 Street, Porto Alegre 90050-170, Rio Grande do Sul, Brazil. matheuswbecker@gmail.com |
| Key Words |
Liver injury; Chemical and drug-induced liver injury; COVID-19; SARS-CoV-2; Pharmacovigilance |
| Core Tip |
Coronavirus disease 2019 (COVID-19) is a multisystemic disease, and liver manifestations are an important aspect to be considered. One should pay attention to drug-induced liver injury, especially considering the off-label use of drugs in prophylactic and therapeutic regimens applied on large scales. A review of liver damage in patients with COVID-19 returned three studies involving remdesivir, tocilizumab, and a pharmacovigilance study. Liver disorders in COVID-19 patients and the use of several concomitant off-label drugs — potentially causing further liver damage — should be a warning sign for rapid identification and early intervention, thus preventing severe impairment in patients. |
| Publish Date |
2021-09-22 08:09 |
| Citation |
Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: A review for clinical practice. World J Hepatol 2021; 13(9): 1143-1153 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i9/1143.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i9.1143 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
